Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
15.12 AUD | +0.27% | +1.88% | -5.06% |
04-29 | Clinuvel Pharmaceuticals Obtains Orphan Drug Designation in Europe for Xeroderma Pigmentosum Treatment; Shares Up 3% | MT |
03-14 | Clinuvel Pharmaceuticals Launches Share Buyback Program | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.06% | 518M | |
-0.26% | 89.46B | |
+2.76% | 40.74B | |
-9.06% | 33.03B | |
+55.32% | 24.68B | |
-16.61% | 15.12B | |
-9.14% | 12.81B | |
-12.11% | 11.79B | |
-43.61% | 11.64B | |
+7.79% | 8.9B |
- Stock Market
- Equities
- CUV Stock
- News Clinuvel Pharmaceuticals Limited
- Clinuvel Pharmaceuticals Obtains Orphan Drug Designation in Europe for Xeroderma Pigmentosum Treatment; Shares Up 3%